DrugPatentWatch Database Preview
DAURISMO Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Daurismo, and when can generic versions of Daurismo launch?
Daurismo is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug.
This drug has sixty-eight patent family members in forty-five countries.
The generic ingredient in DAURISMO is glasdegib maleate. One supplier is listed for this compound. Additional details are available on the glasdegib maleate profile page.
US ANDA Litigation and Generic Entry Outlook for Daurismo
Daurismo will be eligible for patent challenges on November 21, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 13, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for DAURISMO
| International Patents: | 68 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 37 |
| Patent Applications: | 5 |
| Drug Prices: | Drug price information for DAURISMO |
| DailyMed Link: | DAURISMO at DailyMed |
Generic Entry Opportunity Date for DAURISMO
Generic Entry Date for DAURISMO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for DAURISMO
| 1-((2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate salt |
| 1-((2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleatesalt |
| 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea |
| 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea(PF-04449913) |
| 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea |
| 1095173-27-5 |
| 2030410-25-2 |
| 2640AH |
| 4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)-benzonitrile |
| BC600416 |
| BDBM50385635 |
| C21H22N6O |
| CHEBI:145428 |
| CHEMBL2043437 |
| CS-2731 |
| D10636 |
| D11107 |
| Daurismo (TN) |
| DB11978 |
| EX-A858 |
| Glasdegib |
| Glasdegib (PF-04449913) |
| Glasdegib (USAN/INN) |
| Glasdegib [USAN:INN] |
| Glasdegib maleate |
| Glasdegib maleate (JAN) |
| glasdegib-pf-04449913 |
| Glasdegib(PF-04449913) |
| glasdegibum |
| GTPL8201 |
| HY-16391 |
| J-690029 |
| K673DMO5H9 |
| LQT-B00722 |
| MFCD25976839 |
| N-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)urea |
| N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-N'-(4-cyanophenyl)urea |
| NCGC00378600-02 |
| PF 04449913 |
| PF-04449913 |
| PF-04449913 maleate |
| PF-04449913 maleate salt, >=98% (HPLC) |
| PF-04449913;Glasdegib |
| PF-4449913 |
| PF-913 |
| Q27077810 |
| QC-11459 |
| SB16679 |
| SCHEMBL18171548 |
| SCHEMBL2068480 |
| SFNSLLSYNZWZQG-VQIMIIECSA-N |
| TH2EV99S4Z |
| UNII-K673DMO5H9 |
| UNII-TH2EV99S4Z |
| Urea, N-((2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl)-N'-(4-cyanophenyl)-, (2Z)-2-butenedioate (1:1) |
| Urea, N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)- |
| Z-3230 |
| ZINC68251434 |
US Patents and Regulatory Information for DAURISMO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DAURISMO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Chile | 2008001922 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016170451 | Start Trial |
| South Korea | 20170129245 | Start Trial |
| Eurasian Patent Organization | 016888 | Start Trial |
| Brazil | 112017021075 | Start Trial |
| Costa Rica | 11150 | Start Trial |
| Morocco | 31466 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
